Lixte Biotech Hlds (LIXT)

$7.21 -0.46 (-6.00%)
Market Cap 108.29M
Revenue (ttm) 0.00
Net Income (ttm) -6.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 615,000
Avg Vol 284,048
Day's Range N/A - N/A
Shares Out 15.02M
Stochastic %K 36%
Beta 1.24
Analysts Strong Buy
Price Target N/A

Company Profile

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 c...

Industry: Biotechnology
Sector: Healthcare
Phone: 631 830 7092
Fax: 631 982 5050
Website: lixte.com
Address:
433 Plaza Real, Suite 275, Boca Raton, United States
leon_dedrick
leon_dedrick Jul. 7 at 8:17 PM
$LIXT 👀👀
0 · Reply
5grevolution
5grevolution Jul. 7 at 4:36 PM
$LIXT how is st still showing this as LIXT?
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 6 at 12:32 PM
$LIXT LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
0 · Reply
Hodler9
Hodler9 Jul. 6 at 10:48 AM
$GLXG $LIXT $QH $TNON $USDE.X
0 · Reply
beppels
beppels Jul. 6 at 7:37 AM
BEPPELS WL 06.07.: -$NMAD, 7.2 $, 15 mln float, merger plus ticker change from $LIXT today! ✅ - $USDE.X, 2.7 $, 990 k float, fresh despac, spiked from 2 to 8 on wednesday in ah, very thin, 2 is double bottom! ✅ - $GLXG, 1.25 $, 1.4 mln float, China low float near lows, 665 % ctb, hit 5.5 just some weeks ago in pm! ✅ - $TNON, 0.29 $, 20.6 mln float, 902 % ctb, offering closed at 0.38 $, bottom play! ✅ Also watch $QH, UPC, RDGT, BRAI! 👀 🔥 👀
0 · Reply
MarketMaestro1
MarketMaestro1 Jul. 5 at 9:48 PM
FULL LIST OF STOCKS THAT CAN RUN 50-100%+ NEXT WEEK OR HAS MOMENTUM $JEM 900% CTB WITH 0 SHARES $UPC 750% CTB ; TINY FLOAT; LOTS OF CASH; ==>KEEP THIS ON RADAR $SDOT LAST WEEKS RUNNER; MUST HOLD $48 $CLRO PREMARKET ; $6.15 PULLBACK ==> ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical 3 days ago $LIXT MERGER AND TICKER CHANGE. BEPPELS PLAY BUT: All these names are highly volatile. That’s why the right entry matters more than ever — not just to maximize gains, but also to control risk. And that’s exactly what we focus on with all subscribers.
0 · Reply
TwongStocks
TwongStocks Jul. 2 at 6:36 PM
$LIXT Equity Corporate Actions Alert #2026 - 469 Information Regarding the Reverse Merger of Lixte Biotechnology Holdings, Inc. (LIXT) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2026-469 The reverse merger of Lixte Biotechnology Holdings, Inc. (LIXT) with Nomad Power Solutions, Inc. became effective today, Thursday, July 2, 2026. As a result, the common stock of Lixte Biotechnology Holdings, Inc. will undergo a change of corporate name and symbol. The CUSIP number will remain unchanged. Current Company Name & Symbol: Lixte Biotechnology Holdings, Inc. $LIXT New Company Name & Symbol: Nomad Power Solutions, Inc. $NMAD Marketplace Effective Date: Monday, July 6, 2026
0 · Reply
DollarRollers
DollarRollers Jul. 2 at 1:47 PM
$LIXT lets go to 10$
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 2 at 12:33 PM
$LIXT Completes Merger with Nomad Transportable Power Systems
0 · Reply
GreenblacksJusDCA
GreenblacksJusDCA Jul. 1 at 6:29 PM
$LIXT only here for the night
0 · Reply
Latest News on LIXT
AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD

Jul 6, 2026, 11:40 AM EDT - 8 days ago

AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD

LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

Jul 6, 2026, 8:30 AM EDT - 9 days ago

LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS

Jul 2, 2026, 8:30 AM EDT - 13 days ago

LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS

LIXTE Joins Russell Microcap Index

Jun 26, 2026, 8:30 AM EDT - 19 days ago

LIXTE Joins Russell Microcap Index

LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026

Jun 18, 2026, 8:30 AM EDT - 27 days ago

LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026

LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)

Jun 12, 2026, 8:30 AM EDT - 4 weeks ago

LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)

LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth

Jun 3, 2026, 8:30 AM EDT - 6 weeks ago

LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth

LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

Jun 1, 2026, 8:50 AM EDT - 6 weeks ago

LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

May 14, 2026, 5:18 PM EDT - 2 months ago

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

Apr 13, 2026, 8:00 AM EDT - 3 months ago

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

Mar 31, 2026, 3:45 PM EDT - 3 months ago

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

Feb 18, 2026, 8:00 AM EST - 5 months ago

LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

Jan 21, 2026, 8:00 AM EST - 6 months ago

DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

Jan 20, 2026, 8:00 AM EST - 6 months ago

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

Dec 23, 2025, 8:00 AM EST - 7 months ago

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

Dec 8, 2025, 8:30 AM EST - 7 months ago

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

Dec 3, 2025, 11:00 AM EST - 7 months ago

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

Dec 3, 2025, 8:00 AM EST - 7 months ago

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

Nov 25, 2025, 8:30 AM EST - 8 months ago

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

Oct 29, 2025, 8:00 AM EDT - 9 months ago

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Oct 16, 2025, 8:00 AM EDT - 9 months ago

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

Sep 16, 2025, 8:30 AM EDT - 10 months ago

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

Sep 15, 2025, 5:40 PM EDT - 10 months ago

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

Sep 10, 2025, 4:05 PM EDT - 10 months ago

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

Sep 5, 2025, 8:35 AM EDT - 11 months ago

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

Sep 3, 2025, 8:00 AM EDT - 11 months ago

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

Aug 27, 2025, 8:15 AM EDT - 11 months ago

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

Aug 25, 2025, 8:05 AM EDT - 11 months ago

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

Aug 19, 2025, 11:18 AM EDT - 11 months ago

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

LIXTE Biotechnology Holdings Provides Corporate Update

Aug 18, 2025, 8:00 AM EDT - 11 months ago

LIXTE Biotechnology Holdings Provides Corporate Update

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Aug 14, 2025, 9:06 PM EDT - 11 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

Aug 14, 2025, 8:05 AM EDT - 11 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

Aug 13, 2025, 8:49 AM EDT - 1 year ago

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

Aug 13, 2025, 7:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Jul 16, 2025, 8:05 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

Jul 9, 2025, 5:15 PM EDT - 1 year ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Jul 9, 2025, 8:05 AM EDT - 1 year ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Jul 8, 2025, 2:57 PM EDT - 1 year ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Jul 2, 2025, 4:05 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Jul 1, 2025, 4:15 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Mar 31, 2025, 8:30 AM EDT - 1 year ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Mar 27, 2025, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Feb 25, 2025, 8:30 AM EST - 1 year ago

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 13, 2025, 10:35 AM EST - 1 year ago

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 11, 2025, 8:42 AM EST - 1 year ago

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Feb 10, 2025, 5:00 PM EST - 1 year ago

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Sep 4, 2024, 8:30 AM EDT - 2 years ago

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Aug 26, 2024, 8:30 AM EDT - 2 years ago

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Biotechnology Provides Update On Recent Activities and Developments

Aug 19, 2024, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Provides Update On Recent Activities and Developments

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Aug 15, 2024, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

leon_dedrick
leon_dedrick Jul. 7 at 8:17 PM
$LIXT 👀👀
0 · Reply
5grevolution
5grevolution Jul. 7 at 4:36 PM
$LIXT how is st still showing this as LIXT?
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 6 at 12:32 PM
$LIXT LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
0 · Reply
Hodler9
Hodler9 Jul. 6 at 10:48 AM
$GLXG $LIXT $QH $TNON $USDE.X
0 · Reply
beppels
beppels Jul. 6 at 7:37 AM
BEPPELS WL 06.07.: -$NMAD, 7.2 $, 15 mln float, merger plus ticker change from $LIXT today! ✅ - $USDE.X, 2.7 $, 990 k float, fresh despac, spiked from 2 to 8 on wednesday in ah, very thin, 2 is double bottom! ✅ - $GLXG, 1.25 $, 1.4 mln float, China low float near lows, 665 % ctb, hit 5.5 just some weeks ago in pm! ✅ - $TNON, 0.29 $, 20.6 mln float, 902 % ctb, offering closed at 0.38 $, bottom play! ✅ Also watch $QH, UPC, RDGT, BRAI! 👀 🔥 👀
0 · Reply
MarketMaestro1
MarketMaestro1 Jul. 5 at 9:48 PM
FULL LIST OF STOCKS THAT CAN RUN 50-100%+ NEXT WEEK OR HAS MOMENTUM $JEM 900% CTB WITH 0 SHARES $UPC 750% CTB ; TINY FLOAT; LOTS OF CASH; ==>KEEP THIS ON RADAR $SDOT LAST WEEKS RUNNER; MUST HOLD $48 $CLRO PREMARKET ; $6.15 PULLBACK ==> ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical 3 days ago $LIXT MERGER AND TICKER CHANGE. BEPPELS PLAY BUT: All these names are highly volatile. That’s why the right entry matters more than ever — not just to maximize gains, but also to control risk. And that’s exactly what we focus on with all subscribers.
0 · Reply
TwongStocks
TwongStocks Jul. 2 at 6:36 PM
$LIXT Equity Corporate Actions Alert #2026 - 469 Information Regarding the Reverse Merger of Lixte Biotechnology Holdings, Inc. (LIXT) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2026-469 The reverse merger of Lixte Biotechnology Holdings, Inc. (LIXT) with Nomad Power Solutions, Inc. became effective today, Thursday, July 2, 2026. As a result, the common stock of Lixte Biotechnology Holdings, Inc. will undergo a change of corporate name and symbol. The CUSIP number will remain unchanged. Current Company Name & Symbol: Lixte Biotechnology Holdings, Inc. $LIXT New Company Name & Symbol: Nomad Power Solutions, Inc. $NMAD Marketplace Effective Date: Monday, July 6, 2026
0 · Reply
DollarRollers
DollarRollers Jul. 2 at 1:47 PM
$LIXT lets go to 10$
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 2 at 12:33 PM
$LIXT Completes Merger with Nomad Transportable Power Systems
0 · Reply
GreenblacksJusDCA
GreenblacksJusDCA Jul. 1 at 6:29 PM
$LIXT only here for the night
0 · Reply
rockitpicks
rockitpicks Jun. 29 at 10:49 PM
$LIXT Steady as she goes. Still adamant this is going north if $40.00 by year end.
0 · Reply
money_honey
money_honey Jun. 29 at 7:41 PM
$LIXT Quiet climber.
0 · Reply
rockitpicks
rockitpicks Jun. 15 at 5:50 PM
$LIXT Simple DD on the most recent press release tells you all you need to know....$20.00 plus incoming
1 · Reply
Scoty_D
Scoty_D Jun. 12 at 3:41 PM
$LIXT Uh oh is Stuart Porter shorting? You dog you!
0 · Reply
Scoty_D
Scoty_D Jun. 12 at 2:07 PM
$LIXT oh snap, name change incoming, to cover up tainted name. Sheeeeeeet!
0 · Reply
Scoty_D
Scoty_D Jun. 12 at 2:05 PM
$LIXT Boooooooo! Be better!!!!
0 · Reply
DARKP00L
DARKP00L Jun. 12 at 1:37 PM
$LIXT 08:32 on Jun. 12 2026 LIXTE Biotechnology To Acquire NOMAD Transportable Power Systems; Terms Not Disclosed #tradeideas
0 · Reply
xELEMENTx
xELEMENTx Jun. 11 at 6:21 PM
$ABAT I just asked Claude to help me understand if there is a connection with space exploration, etc. and this is remarkable: $LI $ALTM $LIXT — Lithium recycling isn't hype, it's structural. IEA 2025: demand grows 5x by 2040. Recycling cuts mining need 20–35% by 2050, drops CO₂ 80% vs. virgin material. Deficit is already here — S&P forecasts supply goes negative in 2026. EVs consumed ~70% of 2025 output. US launched a $12B strategic Li reserve (Project Vault, Feb 2026). Space side: NASA/JAXA ISS test showed solid-state Li battery lost only 2% capacity after 434 days in open space. Perseverance runs dual 140Wh Li packs on Mars right now. Deep space missions targeting Jupiter's moons require Li systems rated 20+ years in radiation. At $10K/kg launch cost, resupply isn't viable — recycling is load-bearing infrastructure. Li salts confirmed on Mars, making closed-loop recycling physically possible on-site. This isn't ESG. It's survival on two planets. #lithium #minerals #space
0 · Reply
xELEMENTx
xELEMENTx Jun. 11 at 5:49 PM
$ABAT I just asked Claude to help me understand if there is a connection with space exploration, etc. and this is remarkable: $LI $ALTM $LIXT — Lithium recycling isn't hype, it's structural. IEA 2025: demand grows 5x by 2040. Recycling cuts mining need 20–35% by 2050, drops CO₂ 80% vs. virgin material. Deficit is already here — S&P forecasts supply goes negative in 2026. EVs consumed ~70% of 2025 output. US launched a $12B strategic Li reserve (Project Vault, Feb 2026). Space side: NASA/JAXA ISS test showed solid-state Li battery lost only 2% capacity after 434 days in open space. Perseverance runs dual 140Wh Li packs on Mars right now. Deep space missions targeting Jupiter's moons require Li systems rated 20+ years in radiation. At $10K/kg launch cost, resupply isn't viable — recycling is load-bearing infrastructure. Li salts confirmed on Mars, making closed-loop recycling physically possible on-site. This isn't ESG. It's survival on two planets. #lithium #criticalmineral #EVs #space
0 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 10 at 1:54 PM
$LIXT Outstanding article that hits the mark on LIXT's current state. So if you want to refresh your LIXT insights or learn about LIXT from scratch, this is a must read. https://everyticker.com/quote/LIXT/analysis/lixt-s-amplifier-gambit-a-high-risk-bet-on-combination-oncology-at-the-edge-of-viability-nasdaq-lixt
0 · Reply
DavidScott
DavidScott Jun. 8 at 3:11 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $LIXT $FRSX $PHUN $CAN $SERV
0 · Reply
DARKP00L
DARKP00L Jun. 3 at 1:09 PM
$LIXT 08:38 on Jun. 03 2026 LIXTE Biotechnology Announces ~$16.57M Registered Direct Offering, Selling ~2.625M Shares And Pre-Funded Warrants At A Combined Price Of $6.31 #tradeideas
0 · Reply